Patents by Inventor Soomin RYU

Soomin RYU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250074974
    Abstract: The present invention relates to a fusion protein comprising an anti-C3b antibody or an anti-C5 antibody and an angiogenesis inhibitor, and a composition for treating eye diseases, particularly macular degeneration, by using the same. The protein may not only inhibit complement-related pathways, but can also efficiently regulate angiogenesis. Therefore, the fusion protein dimer can be effectively used to treat and prevent complement-related diseases, particularly eye diseases such as macular degeneration, and thus has high industrial applicability.
    Type: Application
    Filed: December 27, 2022
    Publication date: March 6, 2025
    Inventors: Eu Ddeum Chung, Soomin Ryu, Donggeon Kim, Jihoon Chang, Byoung Chul Lee
  • Publication number: 20230295327
    Abstract: The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to CD20. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-CD20 antibody is implemented in one antibody, IL-12 is specifically localized to a tumor site by targeting CD20, which is specifically expressed in a tumor at a high level, thereby efficiently treating cancer. Therefore, the bispecific antibody can be utilized as a pharmaceutical composition for anticancer treatment, and thus has a high potential for industrial application.
    Type: Application
    Filed: August 10, 2021
    Publication date: September 21, 2023
    Inventors: Dahea LEE, Soomin RYU, Donggeon KIM, Jihoon CHANG, Byoung Chul LEE
  • Publication number: 20230295258
    Abstract: The present invention provides a bispecific antibody comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP. The bispecific antibody exhibits an anticancer effect by IL-12. In particular, when the anti-FAP antibody is implemented in one antibody, cancer may be efficiently treated by specifically targeting FAP expressed highly in a tumor, and specifically localizing IL-2 to the tumor site. Therefore, the bispecific antibody may be utilized as a pharmaceutical composition for anticancer treatment, and thus has high industrial application potential.
    Type: Application
    Filed: August 10, 2021
    Publication date: September 21, 2023
    Inventors: Donggeon KIM, Soomin RYU, Dahea LEE, Dongsu KIM, Jihoon CHANG, Byoung Chul LEE
  • Publication number: 20230242633
    Abstract: Provided is a fusion protein dimer containing an extracellular domain of CRIg or a fragment thereof, and a protein that specifically binds to VEGF. The protein may not only inhibit complement-related pathways, but also effectively modulate angiogenesis. Therefore, the fusion protein dimer may be effectively used for the treatment and prevention of complement-related diseases, specifically, eye diseases such as macular degeneration, and thus a high possibility of being industrially used.
    Type: Application
    Filed: July 7, 2021
    Publication date: August 3, 2023
    Inventors: Eu Ddeum CHUNG, Soomin RYU, Donggeon KIM, Jihoon CHANG, Byoung Chul LEE